Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer
The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Insulin-like growth factor-1 (IGF-1) leads via its receptor IGF-1R to the activation of the PI3K/Akt pathway, providing antiapoptotic signals to pre-malignant and malignant cells. In pancreatic cancer, IGF-1 and its receptor are constitutively overexpressed. Mammalian target of rapamycin (mTOR) is the main mediator of mitogenic stimuli transduced by PI3K/Akt. Interestingly, inhibition of mTOR activates PI3K/Akt by up-regulating IGF-1R signaling. Several targeted agents have been developed to inhibit the activity of IGF-1 or to block IGF-1R. These pharmaceuticals may offer additional ways of stimulating apoptosis in neoplastic cells. Yet, there are difficulties in targeting this pathway: The ideal anti-cancer drug target is expressed only in cancer cells; however, IGF-1 and its receptor IGF-1R are ubiquitously expressed throughout the body. Moreover, when using antibodies against IGF-1R, the structurally similar insulin receptor might also be blocked, leading to hyperglycemia as a severe side effect. There are currently several phase I/II trials investigating IGF-1 and its receptor as a drug target in various kinds of cancer. Specifically, therapeutic effects on pancreatic cancer by combining a humanized monoclonal antibody against IGF-1R with other chemotherapeutics are being investigated. To improve the clinical outcome of mTOR inhibitors such as everolimus, it has been suggested to use combination therapies of mTOR inhibitors and IGF-1/IGF-1R inhibitors. In theory, this would counterbalance the feedback effects of mTOR inhibition on IGF-1 signaling. In conclusion, IGF-1 and its receptor are promising new drug targets in cancer therapy. Combination therapies of IGF-1/IGF-1R inhibitors and mTOR inhibitors could improve the clinical outcome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ability to achieve deep and durable inhibition of KRAS-dependent signaling is dependent on the susceptibility of KRAS mutated tumor cells to feedback reactivation of KRAS and pathways that mediate KRASdependent signaling[30, 31].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [31]
Citations
Cites
1 retracted
Karp, D. D., Paz-Ares, L. G., Novello, S., Haluska, P., Garland, L., Cardenal, F., Blakely, L. J., Eisenberg, P. D., Langer, C. J., Blumenschein, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9331 · Cited by 260
RetractedUpstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,996
Ullrich, A., Gray, A., Tam, A. W., Yang-Feng, T., Tsubokawa, M., Collins, C., Henzel, W., Le Bon, T., Kathuria, S., & Chen, E. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04528.x · Cited by 1,844
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E., & Pollak, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10384-1 · Cited by 1,823
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314
Ma, J., Pollak, M. N., Giovannucci, E., Chan, J. M., Tao, Y., Hennekens, C. H., & Stampfer, M. J. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.620 · Cited by 1,119
Frasca, F., Pandini, G., Scalia, P., Sciacca, L., Mineo, R., Costantino, A., Goldfine, I. D., Belfiore, A., & Vigneri, R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3278 · Cited by 902
Baxter, R. C. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.278.6.e967 · Cited by 672
Garcı́a-Echeverrı́a, C., Pearson, M. A., Marti, A., Meyer, T., Mestan, J., Zimmermann, J., Gao, J., Brueggen, J., Capraro, H.-G., Cozens, R., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00051-0 · Cited by 542
Pandini, G., Frasca, F., Mineo, R., Sciacca, L., Vigneri, R., & Belfiore, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202766200 · Cited by 500
Dunn, S. E., Kari, F. W., French, J. E., Leininger, J. R., Travlos, G. S., Wilson, R., & Barrett, J. C. (1997) · PubMed · Cited by 481
IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms
Mohan, S., & Baylink, D. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750019 · Cited by 444
The IGF-I receptor in cell growth, transformation and apoptosis
Baserga, R., Hongo, A., Rubini, M., Prisco, M., & Valentinis, B. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00007-3 · Cited by 439
Monoclonal antibodies to receptors for insulin and somatomedin-C.
Kull, F. C., Jacobs, S., Su, Y. F., Svoboda, M. E., Van Wyk, J. J., & Cuatrecasas, P. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32449-9 · Cited by 423
Arteaga, C. L., Kitten, L. J., Coronado, E. B., Jacobs, S., Kull, F. C., Allred, D. C., & Osborne, C. K. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114315 · Cited by 328
Bergmann, U., Funatomi, H., Yokoyama, M., Beger, H. G., & Korc, M. (1995) · PubMed · Cited by 304
Scotlandi, K., Manara, M. C., Nicoletti, G., Lollini, P.-L., Lukas, S., Benini, S., Croci, S., Perdichizzi, S., Zambelli, D., Serra, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3192 · Cited by 299
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., Enzinger, P. C., Allen, B., Clark, J. W., Ryan, D. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9514 · Cited by 297
Rapamycins: Mechanisms of Action and Cellular Resistance
Huang, S., Bjornsti, M.-A., & Houghton, P. J. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.3.360 · Cited by 287
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
Carboni, J. M., Wittman, M., Yang, Z., Lee, F., Greer, A., Hurlburt, W., Hillerman, S., Cao, C., Cantor, G. H., Dell-John, J., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0499 · Cited by 280
Lopez, T., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00055-7 · Cited by 268
Pandini, G., Vigneri, R., Costantino, A., Frasca, F., Ippolito, A. M., Fujita‐Yamaguchi, Y., Siddle, K., Goldfine, I. D., & Belfiore, A. (1999) · PubMed · Cited by 255
Grewe, M., Gansauge, F., Schmid, R. M., Adler, G., & Seufferlein, T. T. W. (1999) · PubMed · Cited by 235
Buscà, R., Bertolotto, C., Ortonne, J.-P., & Ballotti, R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.31824 · Cited by 231
The Insulin Receptor and Its Cellular Targets1
Kido, Y., Nakae, J., & Accili, D. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7306 · Cited by 223
Párrizas, M., Gazit, A., Levitzki, A., Wertheimer, E., & LeRoith, D. (1997) · Endocrinology · doi:10.1210/en.138.4.1427 · Cited by 212
Dunn, S. E., Hardman, R. A., Kari, F. W., & Barrett, J. C. (1997) · PubMed · Cited by 204
Kurzrock, R., Patnaik, A., Aisner, J., Warren, T., Leong, S., Benjamin, R., Eckhardt, S. G., Eid, J. E., Greig, G., Habben, K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3220 · Cited by 196
Graham, C. H., Forsdike, J., Fitzgerald, C. J., & Macdonald-Goodfellow, S. K. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990209)80:4<595::aid-ijc18>3.0.co;2-b · Cited by 195
Gooch, J. L., Van Den Berg, C. L., & Yee, D. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006208721167 · Cited by 191
IGF-1 Receptor Inhibitors in Clinical Trials—Early Lessons
Weroha, S. J., & Haluska, P. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9104-6 · Cited by 178
Substrate Competitive Inhibitors of IGF-1 Receptor Kinase
Blum, G., Gazit, A., & Levitzki, A. (2000) · Biochemistry · doi:10.1021/bi001516y · Cited by 161
Surmacz, E. (2003) · Oncogene · doi:10.1038/sj.onc.1206772 · Cited by 155
Goya, M., Miyamoto, S., Nagai, K., Ohki, Y., Nakamura, K., Shitara, K., Maeda, H., Sangai, T., Kodama, K., Endoh, Y., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0919 · Cited by 138
Presence of somatomedin receptors on primary human breast and colon carcinomas
Pollak, M., Perdue, J. F., Margolese, R. G., Baer, K. A., & Richard, M. (1987) · Cancer Letters · doi:10.1016/0304-3835(87)90218-7 · Cited by 136
Wang, Y., & Sun, Y. (2002) · Current Cancer Drug Targets · doi:10.2174/1568009023333863 · Cited by 123
Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer
Belfiore, A., Pandini, G., Vella, V., Squatrito, S., & Vigneri, R. (1999) · Biochimie · doi:10.1016/s0300-9084(99)80088-1 · Cited by 106
IGF-1: Old Growth Factor Shines as New Drug Target
Garber, K. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/97.11.790 · Cited by 86
Vasilcanu, R., Vasilcanu, D., Rosengren, L., Natalishvili, N., Sehat, B., Yin, S., Girnita, A., Axelson, M., Girnita, L., & Larsson, O. (2007) · Oncogene · doi:10.1038/sj.onc.1210797 · Cited by 78
Insulin-like growth factor-I and binding protein-3 in relation to childhood leukaemia
Petridou, E. T., Dessypris, N., Spanos, E., Mantzoros, C. S., Skalkidou, A., Kalmanti, M., Koliouskas, D. E., Kosmidis, H. V., Panagiotou, J. P., Piperopoulou, F., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990209)80:4<494::aid-ijc2>3.0.co;2-k · Cited by 64
Alami, N., Pagé, V., Yu, Q., Jerome, L., Paterson, J., Shiry, L., & Leyland-Jones, B. R. (2008) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2008.04.002 · Cited by 60
Heinrich, T., Grädler, U., Böttcher, H., Blaukat, A., & Shutes, A. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100044h · Cited by 48
Tolcher, A. W., Patnaik, A., Till, E., Takimoto, C. H. M., Papadopoulos, K. P., Massard, C., Méry-Mignard, D., Deslandes, A., Ozoux, M., & Soria, J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3582 · Cited by 32
Sarantopoulos, J., Mita, A. C., Mulay, M., Romero, O., Lu, J., Capilla, F., Chen, L., Hwang, Y. J., Friberg, G. R., & Rosen, L. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3583 · Cited by 31
Garrouste, F. L., Remacle-Bonnet, M. M., Lehmann, M., Marvaldi, J. L., & Pommier, G. J. (1997) · Endocrinology · doi:10.1210/endo.138.5.5100 · Cited by 29
Desai, J., Solomon, B., Davis, I. D., Lipton, L. R., Hicks, R., Scott, A. M., Park, J., Clemens, P. L., Gestone, T. A., & Finckenstein, F. G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3104 · Cited by 26
Smith, D. C., Britten, C. D., Clary, D. O., Nguyen, L. T., Woodard, P., & Hurwitz, H. I. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3512 · Cited by 26
Haluska, P., Shaw, H. M., Batzel, G. N., Molife, L. R., Adjei, A. A., Yap, T. A., Roberts, M. L., Gualberto, A., & Bono, J. S. D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3586 · Cited by 23
Javle, M. M., Varadhachary, G. R., Shroff, R. T., Bhosale, P., Overman, M. J., Weatherly, J., Wolff, R. A., & Abbruzzese, J. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.4039 · Cited by 22
Lindsay, C. R., Chan, E., Evans, T. R. J., Campbell, S., Bell, P., Stephens, A. W., Franke, A., Poondru, S., Rothenberg, M. L., & Puzanov, I. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.2559 · Cited by 22
Jenkins, P. (1998) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(98)00093-9 · Cited by 11
Harzstark, A. L., Ryan, C. J., Diamond, M. I., Jones, J. O., Zavodovskaya, M., Maddux, B. A., Claros, C., Goldfine, I. D., & Small, E. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.15500 · Cited by 11
mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.
Gerullis, H., Ecke, T., Eimer, C., Heuck, C. J., & Otto, T. (2010) · PubMed · Cited by 10
Philip, P. A., Goldman, B. H., Ramanathan, R. K., Lenz, H., Lowy, A. M., Whitehead, R. P., Iqbal, S., Chung, V. M., Benedetti, J., & Blanke, C. D. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.tps223 · Cited by 4
Brevet, M., Shimizu, S., Zhou, Q. G., Olshen, A. B., Zakowski, M. F., Rusch, V. W., & Ladanyi, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e13607 · Cited by 1
Cited by
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02007-7 · Cited by 553
Bailey, J. M., Alsina, J., Rasheed, Z. A., McAllister, F. M., Fu, Y., Plentz, R., Zhang, H., Pasricha, P. J., Bardeesy, N., Matsui, W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.09.050 · Cited by 312
Lipid rafts as major platforms for signaling regulation in cancer
Mollinedo, F., & Gajate, C. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.10.003 · Cited by 308
Mollinedo, F., & Gajate, C. (2020) · Journal of Lipid Research · doi:10.1194/jlr.tr119000439 · Cited by 279
Lu, G., Shang, W., Deng, H., Han, Z., Hu, M., Liang, X., Fang, C., Zhu, X., Fan, Y., & Tian, J. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.12.025 · Cited by 130
Metadata
- Authors
- Rieder, S., W. Michalski, C., Friess, H., & Kleeff, >.
- Affiliations
- Technical University of Munich (DE)
- Venue
- Anti-Cancer Agents in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-06-01
- Volume
- 11
- Issue
- 5
- Pages
- 427-433
- ISSN
- 1568-0118 (ISSN-L)
- 1871-5206
- OpenAlex
- W2167677344
- Cited by
- 50
- References
- 61
- Citations by year
- 2026: 1 · 2025: 4 · 2023: 1 · 2022: 4 · 2021: 6 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 5 · 2015: 5 · 2014: 9 · 2013: 6 · 2012: 2
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Anti-Cancer Agents in Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- insulin-like growth factor I, IGF-1 receptor, pancreatic cancer, PI3K/Akt signaling, mTOR inhibition, everolimus, combination therapy, apoptosis, drug target specificity
- MeSH terms
- Humans, Insulin-Like Growth Factor I, Pancreatic Neoplasms, Signal Transduction, Receptor, IGF Type 1, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.